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Key Points 
• Comorbid psychiatric and/or medical 
conditions largely responsible. 
• Older adults take longer to fall asleep and 
have more nighttime wakefulness. 
• Less slow-wave sleep in older adults. 
• Treatment guided by causes. 
• Cognitive-behavioral therapy is first-line 
treatment. 
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Sleepless in Iowa City 
• Independently functioning 90 yo male with 6 
years of difficulty getting and staying asleep. 
• Tried many meds: alprazolam, temazepam and 
zolpidem. 
• Currently on melatonin 5 mg during the night. 
• PMH: a-fib, BPH, hypertension, arthritis and 
short term memory difficulty.  
• Meds: ASA, metoprolol, memantine, 
omeprazole, oxybutynin, acetaminophen. 
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The rest of the story 
• Wife placed in nursing home 14 months ago. 
• Occasionally worries about finances. 
• 5 times nightly nocturia. 
• No breathing problems or restless legs. 
• Normal physical exam except for irregularly 
irregular rhythm. 
• GDS=2, MOCA= 26/30. 
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Definitions  
Insomnia: difficulty in falling asleep or staying 
asleep, waking up too early or experiencing 
nonrestorative or poor quality sleep. 
Chronic Insomnia: occurring for at least 3 nights 
a week for 1 month or more. 
Primary Insomnia: chronic insomnia without 
specific underlying cause. 
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A. A predominant dissatisfaction with sleep quantity or quality 
with at least one of: difficulty initiating sleep, difficulty 
maintaining sleep, or early morning awakenings 
B. Causes clinically significant distress or impairment 
C. Occurs ≥ 3 nights per week 
D. Present for ≥ 3 months 
E. Occurs despite adequate opportunity for sleep 
F. Not better explained by/occur exclusively during another 
sleep-wake disorder 
G. Not attributable to the physiological effects of a substance 
H. Coexisting mental disorders and medical conditions do not 
adequately explain the predominant complaint of insomnia 
DSM-5: Insomnia Disorder 
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3 P’s of Acute Insomnia 
• Predisposition 
– Anxiety, depression, etc. 
• Precipitation 
– Sudden change in life 
• Perpetuation 
– Poor sleep hygiene 
 
• Ideally treat in the ACUTE phase, before the patient 
develops CHRONIC insomnia 
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Insomnia Epidemiology 
• Complaints have little association with age. 
• Prevalence of sleep disorders increase with 
age. 
• More common in women than men.  
 Women to Men ratio:    
  * young adults RR = 1.28  
  * older adults RR = 1.73 
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Sleep Problems in the Elderly – Epidemiology and 
Impact 
• Sleep complaints are common in older adults 
– 70% experience ≥1 symptom of insomnia1  
– Most common symptom is difficulty maintaining sleep1  
– 35% of individuals aged ≥65 years report nightly awakenings2  
• Insomnia has significant effects on daily lives of elderly  
– Impairments in problem solving and in working and episodic memory3  
• Risk factor for cognitive decline and increases risk of falls4  
1. Jaussent I et al. Am J Geriatr Psychiatry. 2011;19(1):88-97. 
2. Ohayon MM. J Psychiatr Res. 2008;43(1):48-54. 
3. Fortier-Brochu E et al. Sleep Med Rev. 2012;16(1):83-94. 
4. Kamel NS, Gammack JK. Am J Med. 2006;119(6):463-469. 
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Late-life Insomnia 
• Chronic problem: 1/3 of older adults with 
insomnia report severe symptoms at 4 years. 
• Those using hypnotics 1/3 still using at 4 yrs. 
• Women >84 yrs. of age: 80% report sleeping 
difficulties. ( regular ETOH, OTC sleep agents) 
• Predictor of death and NH placement (men). 
• Associated with worse quality of life. 
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Sleep Patterns and Aging 
• waking up earlier 
• increased sleep onset 
latency 
• increased time spent in 
bed 
• increased night time 
awakening 
• increased napping 
• decreased total sleep 
(especially deep) 
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Factors that Adversely Influence Sleep 
Quality 
• Behavioral and environmental factors 
• Psychosocial factors 
• Psychiatric disorders 
• Physical status 
• Medication and drugs 
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Behavioral and Environmental 
• Sleep hygiene 
• Extreme temperature 
• Noise or light 
• Lack of exposure to light 
• Physical inactivity 
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Psychosocial  
• Stress 
• Hyperarousal 
• Social isolation 
• Bereavement 
• Change of residence 
• Hospitalization 
• Work status 
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Psychiatric 
• Depression 
• Anxiety 
• Psychosis 
• Delirium 
• Schizophrenia  
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Physical Status 
• CV disorders 
• Pulmonary disease 
• GI disorders 
• GU disorders 
• Neurodegenerative 
disorders 
• Stroke and Seizures 
• Chronic pain 
• Thyroid disorder 
• Diabetes 
• Menopause 
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Medication and Drugs 
• Alcohol  
• Caffeine 
• Nicotine 
• CNS stimulants 
• Beta blockers 
• Thyroid hormone 
• Ca channel blockers 
• Decongestants 
• Bronchodilators  
• Corticosteroids 
• Anticholinergics 
• Antidepressants 
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Differential for Disordered Sleep 
• Medical Conditions and their Treatments. 
• Sleep-Related Breathing Disorders. 
• Periodic Limb Movements / Restless Legs. 
• Circadian Rhythm Sleep Disorders. 
• REM Sleep Behavior Disorders. 
• Changes in Sleep with Dementia.  
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Obstructive Sleep Apnea 
• Common in older adults, prevalence varies. 
• Consider in pt with treatment resistant 
hypertension. 
• BMI and neck size less predictive in older pt. 
• Many associations: B/P, stroke, dementia, MI 
all-cause mortality. 
• CPAP tolerated in older adults. 
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Restless legs syndrome 
• Uncontrolled urge to move legs 
• Uncomfortable sensation in legs during rest 
• Periodic limb movements. 
• Associated anemia, or renal or neurologic 
disease.  
• Drugs: antiemetics, antipsychotics, SSRIs, 
tricyclics, diphenhydramine.  
• TX: pramipexole, ropinirole, Sinemet, gabapentin 
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Circadian rhythm sleep disorder 
• Common early bedtime and early morning 
awakening ( morning lark//night owl). 
• Sleep log to diagnosis and monitor therapy. 
• Wrist actigraphy or polysomnogram if unclear 
diagnosis. 
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REM behavior disorder 
• Act out dreams 
• Lack of normal muscle atonia during REM 
sleep 
• Rare 
• Associated with: Dementia, Multiple system 
atrophy and Parkinson disease. 
• Polysomnogram to confirm diagnosis. 
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Sleep changes with Dementia 
• Lower sleep efficiency, higher percent N1 
sleep. 
• Circadian rhythm sleep disorders more 
common. ( daytime sleeping, nighttime 
wakefulness) 
• Cholinesterase inhibitors  vivid dreams 
• ? Melatonin effect in Alzheimer disease 
• Some benefit from bright light therapy 
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Evaluation of Sleep 
• Screening questions: is patient satisfied with 
their sleep, fatigue interfering with ADLs, bed 
partner complaints about patient’s sleep? 
• Sleep log for 1-2 weeks.  
• Focused physical exam. 
• Polysomnogram: ? Sleep apnea, narcolepsy, 
violent behaviors during sleep. 
• Wrist actigraphy. 
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Management of Sleep Problems 
• Behavioral and Nonpharmacologic 
Interventions. 
 
 
 
• Pharmacotherapy. 
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Behavioral Interventions 
• Not to be confused with simple sleep hygiene. 
• Cognitive-behavioral therapy CBT-I (stimulus 
control, sleep restriction, cognitive therapy) 
• Exposure to bright light. 
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Components of Cognitive Behavioral Therapy for Insomnia. 
Winkelman JW. CLINICAL PRACTICE. Insomnia Disorder. N Engl J Med 2015 Oct 8;373:1437-1444. doi:10.1056/NEJMcp1412740. 
PMID: 26444730.  
Components of Cognitive Behavioral Therapy for Insomnia. 
These materials provided for reference use at the 43rd Annual Family Medicine Refresher Course for the Family Physician. 
Permission from the author must be sought before reuse or redistribution.
Sleep restriction 
• Intended Effect     
 * increase sleep drive and stabilize  
  circadian rhythm. 
• Directions for Patients    
 * Reduce time in bed to perceived total 
 sleep time (= or > 5-6 hours)  
 * Increase time in bed as sleep efficiency 
 improves. 
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Stimulus control 
• Intended effect     
 * reduce arousal in sleep environment, 
 promote association of bed and sleep 
• Directions for Patients    
 * sleep when sleepy, get out of bed when 
 awake and anxious at night use bed only 
 for sleep or sexual activity (no watching TV 
 in bed) 
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Cognitive therapy 
• Intended effect     
 * restructure maladaptive beliefs about 
 daytime and health consequences of 
 insomnia. 
• Directions for Patients    
 * maintain reasonable expectations about 
 sleep; review previous insomnia 
 experiences, challenging perceived 
 catastrophic consequences.  
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Relaxation therapy 
• Intended effect     
 * reduce physical and psychological 
 arousal in sleep environment. 
• Directions for Patients    
 * practice progressive muscle relaxation, 
 breathing exercise, or meditation. 
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Sleep hygiene 
• Intended effect     
 * reduce behaviors that interfere with 
 sleep drive or increase arousal.  
• Directions for Patients    
 * limit caffeine and alcohol, keep bedroom 
 dark and quiet, avoid napping, increase 
 exercise, remove bedroom clock from 
 sight. 
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Pharmacotherapy 
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• Benzodiazepines 
• Nonbenzodiazepine Benzodiazepine 
Receptor Agonists (Z-hypnotics) 
• Melatonin Receptor Agonists 
• Orexin Receptor Antagonists 
• Antidepressants 
• Antihistamines 
• Natural Products 
 
Available Treatment Options 
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Short-term Use Long-term Use (>3 mos) 
• zolpidem (CR tablet) 
• eszopiclone 
• ramelteon 
• low-dose doxepin 
• suvorexant 
• benzodiazepines 
– estazolam 
– flurazepam 
– quazepam 
– temazepam 
– triazolam 
• zolpidem (tablet, sublingual 
tablet, oral spray) 
• zaleplon 
• phenobarbital* 
• chloral hydrate*† 
FDA-Approved Agents 
*Not recommended  †No longer available 
Schutte-Rodin et al. J Clin Sleep Med 2008 
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Benzodiazepines 
• Benzodiazepines – GABA-A receptors 
– Benefits: cheap, improve sleep latency, total sleep 
time, number of awakenings, sleep quality 
– Disadvantages: 
• More next day effects (drowsy, dizzy) 
• More dependency/withdrawal 
• More rebound symptoms 
• More anterograde amnesia (especially with shorter 
acting agents) 
• Falls and hip fracture risk (long acting) 
Tariq SH. Clin Geriatr Med 2008;24:93-105. 
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NBzRA Agents 
Zolpidem (Ambien) 
• Short half life (2.6 hours, 2.8 
for “CR”) 
• Better for sleep onset 
insomnia 
– Minimal impact on sleep 
architecture 
• “CR” not directly compared 
with Ambien 
• Can see rebound insomnia, 
mild next day drowsiness, 
mild antegrade amnesia 
• “CR” approved for long 
term use 
Zaleplon (Sonata) 
• Ultrashort half-life (1 hour) 
• Better for sleep onset 
insomnia 
– Can increase total sleep time 
and efficiency 
• Can be taken after a middle 
of night awakening 
• Rare rebound and next day 
effects 
• Not approved for long term 
use 
– But reported to be safe for 
long term use in elderly 
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Eszopiclone (Lunesta) 
• Medium half life (5-7 hours) 
• Better for sleep maintenance insomnia 
– Increased total sleep time 49 min 
• Helps with sleep onset (27min) 
• Few next day effects (but longer half life 
suggest risk for next day effects in elderly) 
• Approved for long term use 
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NBzRA Agents 
– Advantages 
• more specific targeting of 
GABA receptors in the brain 
– so less side effects? 
• Data for efficacy up to 6-12 
months (zolpidem, 
eszopiclone) 
• Better for sleep onset 
insomnia – minimal impact 
on sleep architecture 
• May be used for middle of 
night awakenings (low-dose 
zolpidem sublingual tablet, 
zaleplon) 
• Low likelihood of rebound 
insomnia 
 
– Disadvantages 
• Not well studied in the elderly 
(use lower starting doses) 
• Not compared against each 
other 
• More expensive ($65-100 per 
month) 
• Dependence/withdrawal still 
occur 
• Still can increase risk of falls and 
fractures 
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• Literature review for cases of reported abuse or 
dependence with zolpidem or zopiclone through 2002 
• Identified 36 cases with zolpidem, 22 with zopiclone; 
almost all were former drug/alcohol abusers or had 
another psychiatric disorder 
• Because of high prescription rates for these agents, 
authors felt that relative risk of abuse/dependence was 
very low 
• Conclusion: pts with Hx substance abuse and other 
psychiatric disorders at ↑ risk for abusing zolpidem or 
zopiclone 
• Likely that cases of abuse/dependence are 
underreported in the literature 
NBzRA Abuse Potential 
Hajak et al. Addiction 2003 
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Sedative-Hypnotics Risk/Benefit 
• Meta-analysis of 24 studies, > 2400 patients older than age 60 
treated with benzo’s or benzo receptor agonists 
– Benefits – compared to placebo (NNT = 13) 
• Small improvement in sleep quality 
• Sleep time increased (25 minutes) 
• Decrease number of awakenings (0.63) 
– Harms (NNH = 6) 
• Cognitive impact (4.78 times more common) 
• Psychomotor events (2.61 times as common) 
• Daytime fatigue (3.82 times more common) 
 
Glass et al.  BMJ 2005;331:1153-1212. 
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• Mechanism 
– Selectively binds melatonin MT1 and MT2 receptors in the 
hypothalamus, which appear to contribute to normal sleep-
wake cycle 
• Products 
– Ramelteon (Rozerem®) - 2005 
• Pharmacokinetics 
– High-fat meals delay absorption and onset 
 
 
 
• Dosing 
– 8 mg administered within 30 min of bedtime 
Melatonin Receptor Agonists 
Medication Onset (min) Duration Half-life (hr) CYP450 
Metabolism 
ramelteon 30 Short 1-5 1A2 
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Advantages Disadvantages 
• May be less helpful for 
sleep maintenance 
difficulties 
• Not compared to other 
drugs or melatonin. 
• Expensive 
• No rebound insomnia 
• Not a controlled 
substance 
• Small improvement in 
sleep onset (8 min) 
• Improved total sleep time 
(12 min) 
• Increase prolactin levels, 
few other side effects. 
• Approved for chronic use. 
 
Ramelteon Considerations 
Passarella & Duong Am J Health-Syst Pharm 2008; Schutte-Rodin et al. J Clin Sleep Med 2008 
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• Mechanism 
– Blocks binding of wake-promoting neuropeptides orexin A 
and orexin B to receptors OX1R and OX2R, which is thought 
to suppress wake drive 
• Products 
– Suvorexant (Belsomra®) – 2014 
• Pharmacokinetics 
– High-fat meals delay absorption and onset 
 
 
 
• Dosing 
– 10-20 mg administered within 30 min of bedtime 
 
Orexin Receptor Antagonists 
Medication Onset (min) Duration Half-life (hr) CYP450 
Metabolism 
suvorexant 30 Intermediate 12 3A4 
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Advantages Disadvantages 
• C-IV controlled 
substance 
• Expensive 
• No rebound 
insomnia 
• No evidence of 
withdrawal 
Suvorexant Considerations 
These materials provided for reference use at the 43rd Annual Family Medicine Refresher Course for the Family Physician. 
Permission from the author must be sought before reuse or redistribution.
Medication Author, Year, 
Design 
Dose Treatment 
Duration 
Sleep Onset 
Latency 
Total Sleep 
Time 
zolpidem & 
benzos 
Nowell, 1997, 
Meta-analysis 
zolpidem: 
10-15 mg* 
Up to 5 wks -5.95 min +5.64 min 
zaleplon Barbera, 2005, 
Review 
10 mg 4-5 wks -7.9 min Not significant 
eszopiclone Najib, 2006, 
Review 
2-3 mg Up to 4 wks -10 min (2 mg) 
-11.5 min (3 mg) 
+22.1 min (2 mg) 
+31.3 min (3 mg) 
ramelteon Roth, 2006, 
RCT 
4-8 mg 5 wks -7.2 min (4 mg) 
-12.9 min (8 mg) 
Not significant 
suvorexant Herring, 2012, 
RCT 
10-80 mg 4 wks -2.3 min (10 mg) 
-22.3 min (20 mg) 
+22.3 min (10 mg) 
+49.9 min (20 mg) 
Brief Overview of Evidence: 
Benzodiazepines, NBzRAs, Ramelteon 
*Included studies with estazolam, flurazepam, lorazepam, triazolam, temazepam, & 
quazepam at varying doses 
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• Sleep onset difficulties 
– Rapid onset with short half-life 
• zaleplon, ramelteon, triazolam (not first line) 
• Sleep onset and maintenance difficulties 
– Rapid onset and longer half-life 
• zolpidem, eszopiclone, suvorexant 
• Sleep maintenance difficulties 
– Delayed onset with long half-life 
• temazepam, estazolam 
Best Agents for Specific Complaints 
Morin et al. Pharmacotherapy 2007; Schutte-Rodin et al. J Clin Sleep Med 2008 
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• Mechanisms for insomnia 
– H1, 5HT2A, and  muscarinic AChR antagonism 
• Commonly used products 
– trazodone (Desyrel®) - 1981 
– amitriptyline (Elavil®) - 1961 
– doxepin (Sinequan® ) - 1969 
• low-dose tablets (Silenor®) - 2010 
– mirtazapine (Remeron®) - 1996 
• Dosing: generally lower than antidepressant 
doses 
 
Antidepressants 
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• Trazodone: dizziness, sedation, dry mouth, 
hypotension, headache, hangover effect, 
priapism (rare) 
• Amitriptyline/doxepin: sedation, 
anticholinergic effects, cardiac arrhythmias 
• Mirtazapine: sedation, increased appetite, 
weight gain, dry mouth 
Antidepressant Adverse Effects 
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Advantages Disadvantages 
• Limited data  
• TCAs: increased risk of 
confusion and 
anticholinergic effects 
in elderly 
• Not controlled 
substances 
• Best used in 
patients with 
comorbid 
depression 
• Relatively low cost 
Antidepressant Considerations 
Passarella & Duong Am J Health-Syst Pharm 2008; Schutte-Rodin et al. J Clin Sleep Med 2008 
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• Literature review 1980-2003 
• 18 studies identified 
– only 5 with N > 30; only 3 randomized, double-
blind, placebo-controlled 
• 14 of 18 studies enrolled pts with depression 
or dysthymia 
– High variability in methodology 
– Improvements in subjective assessments of sleep 
and objective measures of total sleep time and # 
nighttime awakenings; suggestion of hangover 
effect 
Evidence for Trazodone in Insomnia 
Mendelson J Clin Psychiatry 2005 
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• 306 non-depressed adult pts with DSM-III-defined primary 
insomnia 
• Randomized 1:1:1 to trazodone 50 mg HS, zolpidem 10 mg HS, 
or placebo for 14 days (double-blinded, 10 U.S. sites) 
• Primary outcomes: pt-reported sleep latency & duration  
• Results 
– Week 1: trazodone & zolpidem superior to placebo for sleep 
latency & duration, zolpidem superior to trazodone for latency 
– Week 2: only zolpidem superior to placebo for latency, no 
differences from placebo in duration 
• Limitations: doses not necessarily equivalent, short duration, 
no objective measures, excluded pts with  substance use 
disorders 
Trazodone vs. zolpidem 
Walsh et al. Hum Psychopharm 1998 
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• Mechanisms for insomnia 
– H1 and  muscarinic AChR antagonism 
• Commonly used products 
– diphenhydramine 
– doxylamine  
• Dosing 
– 25-50 mg diphenhydramine or doxylamine 
• Adverse Effects 
– Dizziness, dry mouth, constipation, morning 
sedation; anticholinergic activity (elderly) 
• BEERs list drugs 
Antihistamines 
Multiple OTC products 
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• Meta-analysis of 17 randomized, double-blind, placebo-
controlled trials (N=284 subjects) 
– Melatonin dose range 0.1 - 80 mg (mean 7.4 mg, median 2 mg) 
– Large study heterogeneity; duration up to 4 wks 
– Sleep efficiency improved by 2.2% (95% CI: 0.2 -4.2) and total 
sleep duration ↑ by 12.8 minutes (95% CI: 2.9 - 22.8) across 
studies 
• Randomized, double-blind, placebo controlled trial of 334 
pts aged 55-80 yrs 
– Melatonin 2 mg prolonged-release vs. placebo 
– 26% pts on melatonin had improvement on self-reported 
measures of sleep quality and behavior following wakefulness at 
3 weeks vs. 15 % on placebo [p=0.011, OR: 1.97 (95% CI: 1.14-
3.41)] 
– Mean baseline-adjusted sleep latency time improved by 8.8 
minutes (p=0.028) compared to placebo 
Evidence for Melatonin in Insomnia 
Brzezinski Sleep Med Rev 2005; Wade et al. Curr Med Res Opin 2007 
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Recommendations for Sleepless in 
Iowa City 
• Continue good sleep hygiene. 
• Set expectations.  
• Start tamsulosin at bedtime. 
• Take melatonin 5 mg, ½ hour before bedtime. 
• Discontinue memantine. 
• If sleep not improve consider trazodone 25-50 
mg qhs.   
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Summary 
• Encourage good sleep hygiene 
• Recognize 3 P’s of acute insomnia 
(predisposition, precipitation, perpetuation) 
• Treat comorbidities 
• Low threshold for trazodone or melatonin 
• Rx: Hypnotics…with a plan 
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